Madhukar Trivedi, M.D.

 

Madhukar Trivedi, M.D.
Professor, Chief of the Division of Mood Disorders
Director of the Comprehensive Center for Depression
Department of Psychiatry, UT Southwestern Medical Center


Presentation:  Rating Scales for Use in Psychiatric Clinical Practice


Madhukar H. Trivedi, M.D. is currently a Professor and Chief of the Division of Mood Disorders in the Department of Psychiatry at the University of Texas Southwestern Medical Center at Dallas. He holds the Betty Jo Hay Distinguished Chair in Mental Health. Dr. Trivedi is an established efficacy and effectiveness researcher in the treatment of depression. Dr. Trivedi has focused his research on pharmacological, psychosocial, and other nonpharmacological treatments for depression. Dr. Trivedi has been a principal investigator in multiple clinical trials funded through NIMH and the Texas Department of Mental Health. He is the Principal Investigator of the NIDA-funded “Stimulant Reduction Intervention using Dosed Exercise (STRIDE)” study that tests the effectiveness of adding exercise to treatment as usual in improving drug treatment outcomes. Dr. Trivedi is also Principal Investigator of the Texas Node of the NIDA-funded Clinical Trials Network. Additionally, he was the Principal Investigator of three NIMH grants entitled “CBASP Augmentation for Treatment of Chronic Depression (REVAMP),” “TReatment with Exercise Augmentation for Depression (TREAD),” and “Computerized Decision Support System for Depression (CDSS-D).” He was the Principal Investigator of the Depression Trials Network “Combining Medications to Enhance Depression Outcomes (CO-MED)” trial, which focused on the use of specific antidepressant combinations to increase remission rates by treating a broader spectrum of depressed patients and by capitalizing on additive pharmacological effects. He was also the Co-Principal Investigator of the NIMH-funded project entitled “Sequenced Treatment Alternatives to Relieve Depression (STAR*D).”

Most recently, Dr. Trivedi has been selected to Lead the team conducting the EMBARC project. This project is at the core of the NIMH’s initiative to identify a biosignature for depression. This work will focus on neuroimaging, EEG, clinical and behavioral phenotypes and other blood-based biological markers. His ongoing work as the Lead PI of the EMBARC study provides an extensive background for his contribution to the Neurobiological Markers employed in the study. Note this grant is designed to be a linchpin in the development of a biosignature for depression and is unique in its design to evaluate biomarkers from across full spectrum possible biological markers. As the lead site, he will be able to provide new clinical research opportunities to work at cutting edge of translational research in depression.

Dr. Trivedi has received numerous awards including the Gerald L. Klerman award from the National Depressive and Manic-Depressive Association Scientific Advisory Board-NDMDA and the Psychiatric Excellence Award from the Texas Society of Psychiatric Physicians-TSPP. Dr. Trivedi has mentored multiple psychopharmacology postdoctoral fellows and research track residents over the past many years in Mood and Anxiety Disorders and is the Principal Investigator of an NIMH-funded Postdoctoral T32 training program. He is or has been a member of several institutional review groups of the NIMH. Dr. Trivedi has published over 380 articles and chapters related to the Diagnosis and Treatment of Mood Disorders.


Disclosure: Dr. Trivedi has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

  • Grant Research: NIMH, NIDA, J&J, Janssen Research and Development LLC
  • Honorariums:  Darmouth College, Global Medical Education, University of Illinois Chicago, University of Ottawa, University of TexasHealth Science Center at San Antonio
  • Consultant:  ACADIA Pharmaceuticals Inc., AcademyHealth, Alkeremes Inc., Akili Interactive, Allergan Pharmaceuticals, American Society of Clinical Psychopharmacology (ASCP), Axsome Therapeutics, BlackThorn, Brain Institute Canada (CAN-BIND), Brintellix Global, Engage Health Media, Global Medical Education, Healthcare Global Village, Health Research Associates, Janssen, Jazz Pharmaceuticals, Lundbeck Research USA, Medscape LLC, Navitor, Otsuka America Pharmaceutical Inc., Saatchi, SAGE Therapeutics, Takeda Global Research

Review of Conflicts Policy:  The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming.  For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director.  If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.